Prognostic implication of CEACAM1 expression in squamous cell carcinoma of the larynx: Pilot study.
Aged
Antigens, CD
/ metabolism
Biomarkers, Tumor
/ metabolism
Carcinoma, Squamous Cell
/ metabolism
Cell Adhesion Molecules
/ metabolism
Female
Humans
Immunohistochemistry
Laryngeal Neoplasms
/ metabolism
Male
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Recurrence, Local
/ metabolism
Pilot Projects
Prognosis
CEACAM1
immunotherapy
laryngeal squamous cell carcinoma
prognostic marker
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
11
07
2018
revised:
01
10
2018
accepted:
05
12
2018
pubmed:
26
12
2018
medline:
9
9
2020
entrez:
25
12
2018
Statut:
ppublish
Résumé
CEACAM1, a valuable biomarker for several cancers, have remained unexplored up to the present in laryngeal squamous cell carcinoma (LSCC). We aimed to examine CEACAM1 expression and evaluate its combinational clinical significance for the diagnosis or prognosis and treatment decision making in LSCC. CEACAM1 expression was assessed by immunohistochemistry in 54 LSCCs and evaluate its correlation with clinical and histopathological features. CEACAM subtype 1 (CEACAM1) expression was positive in 50% of the cases. No significant difference was observed in relation to age, gender, tumor size, and tumor stage. CEACAM1 expression correlated with tumor grade, development of local recurrence, node and distant metastasis. Kaplan-Meier survival curves showed that CEACAM1 staining was inversely correlated with both overall and disease-specific 5-year survival. Our study is the first to demonstrate that CEACAM1 expression is associated with an adverse prognosis in LSCC. CEACAM1 is a valuable biomarker and a promising therapeutic target in LSCC.
Sections du résumé
BACKGROUND
CEACAM1, a valuable biomarker for several cancers, have remained unexplored up to the present in laryngeal squamous cell carcinoma (LSCC). We aimed to examine CEACAM1 expression and evaluate its combinational clinical significance for the diagnosis or prognosis and treatment decision making in LSCC.
METHODS
CEACAM1 expression was assessed by immunohistochemistry in 54 LSCCs and evaluate its correlation with clinical and histopathological features.
RESULTS
CEACAM subtype 1 (CEACAM1) expression was positive in 50% of the cases. No significant difference was observed in relation to age, gender, tumor size, and tumor stage. CEACAM1 expression correlated with tumor grade, development of local recurrence, node and distant metastasis. Kaplan-Meier survival curves showed that CEACAM1 staining was inversely correlated with both overall and disease-specific 5-year survival.
CONCLUSIONS
Our study is the first to demonstrate that CEACAM1 expression is associated with an adverse prognosis in LSCC. CEACAM1 is a valuable biomarker and a promising therapeutic target in LSCC.
Substances chimiques
Antigens, CD
0
Biomarkers, Tumor
0
CD66 antigens
0
Cell Adhesion Molecules
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1615-1621Informations de copyright
© 2018 Wiley Periodicals, Inc.